Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of sendai/human parainfluenza type 3 chimera virus in mice

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3942-3951

  Watanabe, Makiko ^a   Mishin, Vasiliy P ^a,d   Brown, Scott A ^a   Russell, Charles J ^a   Boyd, Kelli ^a,e   Sudhakara Babu, Y ^b   Taylor, Garry ^c   Xiong, Xiaoping ^a   Yan, Xiaowei ^a   Portner, Allen ^a   Alymova, Irina V ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BIOCRYST PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCX 2798; BCX 2855; ENZYME INHIBITOR; HN PROTEIN; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CAUSE OF DEATH; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; IMMUNE RESPONSE; INFLUENZA; LETHALITY; LUNG LAVAGE; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS 3; PATHOGENICITY; PRIORITY JOURNAL; PROPHYLAXIS; SENDAI VIRUS; TREATMENT OUTCOME; VIROGENESIS; WEIGHT REDUCTION;

ANIMALS; ANTIVIRAL AGENTS; AZIDES; CELL LINE; CRICETINAE; FEMALE; HAPLORHINI; HEXURONIC ACIDS; HUMANS; MICE; PARAINFLUENZA VIRUS 3, HUMAN; SENDAI VIRUS; SULFONAMIDES;

EID: 70349129529     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00220-09     Document Type: Article

References (50)

1. Alymova, I. V., A. Portner, T. Takimoto, K. L. Boyd, Y. S. Babu, and J. A. McCullers. 2005. The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 49:398-405.
2. Alymova, I. V., G. Taylor, V. P. Mishin, M. Watanabe, K. G. Murti, K. Boyd, P. Chand, Y. S. Babu, and A. Portner. 2008. Loss of the N-linked glycan at residue 173 on human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site. J. Virol. 82:8400-8410.
3. Alymova, I. V., G. Taylor, T. Takimoto, T. H. Lin, P. Chand, Y. S. Babu, C. Li, X. Xiong, and A. Portner. 2004. Efficacy of novel hemagglutinin-neur- aminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob. Agents Chemother. 48:1495-1502.
4. Alymova, I. V., M. Watanabe, K. Boyd, P. Chand, Y. S. Babu, and A. Portner. Efficacy of the novel parainfluenza virus hemagglutinin-neuraminidase 1 inhibitor BCX 2798 in mice - further evaluation. Antivir. Ther., in press.
5. Beckham, J. D., A. Cadena, J. Lin, P. A. Piedra, W. P. Glezen, S. B. Greenberg, and R. L. Atmar. 2005. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J. Infect. 50:322-330. (Pubitemid 40533369)
6. + effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 81:12535-12542.
7. Brownstein, D. G., A. L. Smith, and E. A. Johnson. 1981. Sendai virus infection in genetically resistant and susceptible mice. Am. J. Pathol. 105: 156-163.
8. Buthala, D. A., and M. G. Soret. 1964. Parainfluenza type 3 virus infection in hamsters: virologic, serologic, and pathologic studies. J. Infect. Dis. 114:226-234.
9. Collier, A. M., and W. A. Clyde, Jr. 1977. Model systems for studying the pathogenesis of infections causing bronchiolitis in man. Pediatr. Res. 11:243-246.
10. Counihan, M. E., D. K. Shay, R. C. Holman, S. A. Lowther, and L. J. Anderson. 2001. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr. Infect. Dis. J. 20:646-653.
11. Cox, D. R., and D. Oakes. 1984. Analysis of survival data. Chapman & Hall/CRC, London, United Kingdom.
12. Crennell, S., T. Takimoto, A. Portner, and G. Taylor. 2000. Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase. Nat. Struct. Biol. 7:1068-1074.
13. DeLano, W. L. 2002. The PyMOL molecular graphics system. DeLano Scientific, Palo Alto, CA.
14. Deng, R. T., Z. Y. Wang, A. M. Mirza, and R. M. Iorio. 1995. Localization of a domain on the paramyxovirus attachment protein required for the promotion of cellular fusion by its homologous fusion protein spike. Virology 209:457-469.
15. Faisca, P., D. B. Anh, and D. J. Desmecht. 2005. Sendai virus-induced alterations in lung structure/function correlate with viral loads and reveal a wide resistance/susceptibility spectrum among mouse strains. Am. J. Physiol. Lung Cell. Mol. Physiol. 289:L777-L787.
16. Fry, A. M., A. T. Curns, K. Harbour, L. Hutwagner, R. C. Holman, and L. J. Anderson. 2006. Seasonal trends of human parainfluenza viral infections: United States, 1990-2004. Clin. Infect. Dis. 43:1016-1022.
17. Girard, M. P., T. Cherian, Y. Pervikov, and M. P. Kieny. 2005. A review of vaccine research and development: human acute respiratory infections. Vaccine 23:5708-5724. (Pubitemid 41668877)
18. Hall, C. B. 2001. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344:1917-1928.
19. Henrickson, K. J. 2003. Parainfluenza viruses. Clin. Microbiol. Rev. 16:242-264.
20. Henrickson, K. J., S. Hoover, K. S. Kehl, and W. Hua. 2004. National disease burden of respiratory viruses detected in children by polymerase chain reaction. Pediatr. Infect. Dis. J. 23:S11-S18.
21. + T cells. J. Immunol. 149:1319-1325.
22. Huberman, K., R. W. Peluso, and A. Moscona. 1995. Hemagglutinin- neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle. Virology 214:294-300.
23. Iwane, M. K., K. M. Edwards, P. G. Szilagyi, F. J. Walker, M. R. Griffin, G. A. Weinberg, C. Coulen, K. A. Poehling, L. P. Shone, S. Balter, C. B. Hall, D. D. Erdman, K. Wooten, and B. Schwartz. 2004. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 113:1758-1764.
24. Karron, R. A., and P. L. Collins. 2006. Parainfluenza viruses, p. 1497-1526. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott Williams & Wilkins, Philadelphia, PA.
25. Kato, A., Y. Sakai, T. Shioda, T. Kondo, M. Nakanishi, and Y. Nagai. 1996. Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells 1:569-579. (Pubitemid 126673150)
26. Knott, A. M., C. E. Long, and C. B. Hall. 1994. Parainfluenza viral infections in pediatric outpatients: seasonal patterns and clinical characteristics. Pediatr. Infect. Dis. J. 13:269-273.
27. Lamb, R. A., and G. D. Parks. 2006. Paramyxoviridae: the viruses and their replication, p. 1449-1496. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott Williams & Wilkins, Philadelphia, PA.
28. Lamb, R. A., R. G. Paterson, and T. S. Jardetzky. 2006. Paramyxovirus membrane fusion: lessons from the F and HN atomic structures. Virology 344:30-37.
29. Lawrence, M. C., N. A. Borg, V. A. Streltsov, P. A. Pilling, V. C. Epa, J. N. Varghese, J. L. McKimm-Breschkin, and P. M. Colman. 2004. Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III. J. Mol. Biol. 335:1343-1357.
30. Littell, R. C., G. A. Milliken, W. W. Stroup, and R. Wolfinger. 1996. SAS system for mixed models. SAS Institute, Inc., Cary, NC.
31. Madden, J. F., J. L. Burchette, Jr., and L. P. Hale. 2004. Pathology of parainfluenza virus infection in patients with congenital immunodeficiency syndromes. Hum. Pathol. 35:594-603.
32. Marcolini, J. A., S. Malik, D. Suki, E. Whimbey, and G. P. Bodey. 2003. Respiratory disease due to parainfluenza virus in adult leukemia patients. Eur. J. Clin. Microbiol. Infect. Dis. 22:79-84.
33. Mo, X. Y., M. Sangster, S. Sarawar, C. Coleclough, and P. C. Doherty. 1995. Differential antigen burden modulates the gamma-interferon but not the immunoglobulin response in mice that vary in susceptibility to Sendai virus pneumonia. J. Virol. 69:5592-5598.
34. Murphy, B. R., D. D. Richman, E. G. Chalhub, C. P. Uhlendorf, S. Baron, and R. M. Chanock. 1975. Failure of attenuated temperature-sensitive in- fluenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus. Infect. Immun. 12:62-68.
35. Murphy, T. F., E. J. Dubovi, and W. A. Clyde, Jr. 1981. The cotton rat as an experimental model of human parainfluenza virus type 3 disease. Exp. Lung Res. 2:97-109.
36. Nichols, W. G., L. Corey, T. Gooley, C. Davis, and M. Boeckh. 2001. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 98:573-578.
37. Ottolini, M. G., D. D. Porter, J. C. Blanco, and G. A. Prince. 2002. A cotton rat model of human parainfluenza 3 laryngotracheitis: virus growth, pathology, and therapy. J. Infect. Dis. 186:1713-1717.
38. Parker, J. C., M. D. Whiteman, and C. B. Richter. 1978. Susceptibility of inbred and outbred mouse strains to Sendai virus and prevalence of infection in laboratory rodents. Infect. Immun. 19:123-130.
39. Porotto, M., M. Murrell, O. Greengard, L. Doctor, and A. Moscona. 2005. Influence of the human parainfluenza virus 3 attachment protein's neuraminidase activity on its capacity to activate the fusion protein. J. Virol. 79:2383-2392. (Pubitemid 40204593)
40. Porotto, M., O. Greengard, N. Poltoratskaia, M. A. Horga, and A. Moscona. 2001. Human parainfluenza virus type 3 HN-receptor interaction: effect of 4-guanidino-Neu5Ac2en on a neuraminidase-deficient variant. J. Virol. 75: 7481-7488. (Pubitemid 32738006)
41. Porter, D. D., G. A. Prince, V. G. Hemming, and H. G. Porter. 1991. Pathogenesis of human parainfluenza virus 3 infection in two species of cotton rats: Sigmodon hispidus develops bronchiolitis, while Sigmodon fulviventer develops interstitial pneumonia. J. Virol. 65:103-111.
42. Potier, M., L. Mameli, M. Belisle, L. Dallaire, and S. B. Melancon. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl- α-D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
43. Reed, G., P. H. Jewett, J. Thompson, S. Tollefson, and P. F. Wright. 1997. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J. Infect. Dis. 175:807-813.
44. Sanderson, C. M., H. H. Wu, and D. P. Nayak. 1994. Sendai virus M protein binds independently to either the F or the HN glycoprotein in vivo. J. Virol. 68:69-76. (Pubitemid 24974609)
45. Smith, C. B., R. H. Purcell, J. A. Bellanti, and R. M. Chanock. 1966. Protective effect of antibody to parainfluenza type 1 virus. N. Engl. J. Med. 275:1145-1152.
46. Suzuki, T., A. Portner, R. A. Scroggs, M. Uchikawa, N. Koyama, K. Matsuo, Y. Suzuki, and T. Takimoto. 2001. Receptor specificities of human respiroviruses. J. Virol. 75:4604-4613.
47. Takimoto, T., T. Bousse, E. C. Coronel, R. A. Scroggs, and A. Portner. 1998. Cytoplasmic domain of Sendai virus HN protein contains a specific sequence required for its incorporation into virions. J. Virol. 72:9747-9754. (Pubitemid 28520839)
48. Takimoto, T., K. G. Murti, T. Bousse, R. A. Scroggs, and A. Portner. 2001. Role of matrix and fusion proteins in budding of Sendai virus. J. Virol. 75:11384-11391. (Pubitemid 33063229)
49. Takimoto, T., G. L. Taylor, S. J. Crennell, R. A. Scroggs, and A. Portner. 2000. Crystallization of Newcastle disease virus hemagglutinin- neuraminidase glycoprotein. Virology 270:208-214. (Pubitemid 30256553)
50. Yao, Q. Z., X. L. Hu, and R. W. Compans. 1997. Association of the parain- fluenza virus fusion and hemagglutinin-neuraminidase glycoproteins on cell surfaces. J. Virol. 71:650-656. (Pubitemid 126424277)